Annals of Nuclear Cardiology
Online ISSN : 2424-1741
Print ISSN : 2189-3926
Advance online publication
Showing 1-3 articles out of 3 articles from Advance online publication
  • Mark I. Travin, Ichiro Matsunari, Gregory S. Thomas, Kenichi Nakajima, ...
    Article ID: 18-003
    Published: 2018
    [Advance publication] Released: August 31, 2018
    JOURNALS FREE ACCESS ADVANCE PUBLICATION
    Cardiac denervation is associated with progressive left ventricular (LV) dysfunction, ventricular arrhythmias, and sudden cardiac death (SCD) in heart failure (HF). In this regard, it is important to evaluate cardiac-specific sympathetic nervous system (SNS) function. The radiotracer Iodine-123 meta-iodobenzylguanidine (123I-mIBG) can noninvasively evaluate presynaptic SNS function. Recent multicenter trials have shown 123I-mIBG to have strong predictive value for fatal arrhythmias and cardiac death in HF. 123I-mIBG was initially developed in the USA in the 1970s. In 1992, the Japanese Ministry of Health and Labour approved 123I-mIBG for the assessment of cardiac function. Following approval, the Japanese nuclear cardiology community developed 123I-mIBG imaging services in various medical centers. Japanese groups have been trying to establish the clinical utility of 123I-mIBG and standardize parameters for data acquisition and image analysis. The US Food and Drug Administration (FDA) has approved clinical use of 123I-mIBG for cardiac and non-cardiac imaging. However, clinical use of 123I-mIBG in the US has been very limited. The number of 1123I-mIBG studies in Japan has also been limited. There are similarities and differences between the two countries. To establish the clinical utility of 123I-mIBG in both countries, it is important to characterize the situations of 123I-mIBG in each.
    Download PDF (2033K)
  • Mitsuru Hirano, Rudolf A. Werner, Takahiro Higuchi
    Article ID: 18-00056
    Published: 2018
    [Advance publication] Released: July 31, 2018
    JOURNALS FREE ACCESS ADVANCE PUBLICATION
    Myocardial perfusion imaging (MPI) using advanced PET technology is increasingly used for non-invasive detection and evaluation of coronary artery disease (CAD), but is still limited for clinical use. Recently, 18F labeled PET perfusion tracers have been actively developed as a novel class of PET MPI agents to overcome the disadvantages of conventional PET MPI tracers (15O-labelled water, 13N-ammonia, and 82Rb chloride). This review summarizes the advantages and the feasibility of recent developed 18F labeled tracers in clinical practice.
    Download PDF (174K)
  • Osamu Manabe, Masanao Naya, Tadao Aikawa, Keiichiro Yoshinaga
    Article ID: 18-00064
    Published: 2018
    [Advance publication] Released: July 31, 2018
    JOURNALS FREE ACCESS ADVANCE PUBLICATION
    Oxygen-15-labeled water (15O-H2O) is used as a radiopharmaceutical tracer with positron emission tomography (PET). Its short radioactive half-life permits consecutive rest and stress imaging acquisition while requiring an on-site cyclotron near a PET imaging system. 15O-H2O PET has the disadvantage of being less than ideal for visual assessment; however, its high extraction fraction allows for highly accurate quantification of myocardial blood flow (MBF). Therefore, 15O-H2O is considered to be a gold standard for MBF quantification. This is one of the great advantages of 15O-H2O PET over other PET myocardial perfusion imaging modalities. The purpose of this review is to provide the advantages and characteristics of 15O-H2O PET.
    Download PDF (167K)
feedback
Top